Clinical trial NCT02297230: Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
Official title: Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Breast Cancer
Keywords: Locally Advanced Breast Cancer
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2014-11-21
Enrollment: 44
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Paclitaxel 30 mg/m2 twice/week Trastuzumab 4mg/kg, loading dose, then 2 mg/kg weekly and Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.

\*\*Surgery: Patients will undergo lumpectomy and axillary node dissection or modified radical mastectomy within two months following discontinuation of pre-operative systemic therapy, contingent upon recovery of skin toxicity. Pathologic response will be evaluated at the time of surgery. Additional tissue samples will be collected from the surgical specimen for assessment of tumor molecular characteristics.

\*\*\*All patients may undergo four cycles of post-operative Standard AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) or four cycles of post-operative epirubicin and Cyclophosphamide (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) if doxorubicin is not available Tamoxifen as well or any alternative antihormonal therapy may be prescribed for five years for patients with hormone receptor positive tumors. Herceptin (Trastuzumab) will be prescribed for a total of 1 year since first dose as per standard of care.

Detailed description: Locally Advanced Breast Cancer: T greater than 3.0 cm. HER-2/neu positive. Patients with ipsilateral supraclavicular nodes are eligible. Patients with inflammatory breast cancer or distant metastases are excluded. Patients with prior treatment for their breast cancer are excluded. Patients must have adequate laboratory parameters and normal cardiac function. Patients receive Concurrent Radiation therapy with either Capecitabine, Paclitaxel and Herceptin. Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be 2 mg/kg/week IV over 30 minutes. Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.

Eligibility criteria: Inclusion Criteria:

* Biopsy proven locally advanced breast cancer: STAGE IIB (T must be \> 3.0 cm, N0), IIIA (T0N2, T1N2, T2N2, T3N1), IIIB (T4N0-2).
* HER-2/neu positive ( DAKO 3+ by Immunohistochemistry or FISH positive if Dako 2+)
* Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes.
* Measurable disease required according to the RECIST criteria (Response Evaluation Criteria in Solid Tumors)
* Adequate laboratory values:
* Hgb \> 10
* ANC(Absolute Neutrophil Count) \> 1500
* Platelets \> 150,000
* Cr \< 1.5
* Liver function \< 3 X normal.
* Patient \> 18 years of age.
* Medically and psychologically able to comply with all study requirements.
* ECOG (Eastern cooperative Oncology group) performance score 0-1.
* Signed informed consent.

Exclusion Criteria:

* Stage 0, Stage I, Stage IIA.
* Previous XRT(Radiation therapy) or chemotherapy.
* Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes.
* Inflammatory breast cancer.
* Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil.
* Exclude pregnant or lactating woman.
* Woman of childbearing potential with either a positive or no pregnancy test at baseline.
* Woman of childbearing potential not using a reliable and appropriate contraceptive method.
* (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).
* Patient will agree to continue contraception for 30 days from the date of the last study drug administration.
* Serious concurrent infections.
* Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias ) or myocardial infarction within the last 12 months.
* Patients who have had an organ allograft.
* Patients with severe renal impairment (creatinine clearance below 30 mL/min \[Cockcroft and Gault43\]). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min \[Cockcroft and Gault43\]) at baseline, a dose reduction to 75% of the XELODA starting dose is recommended. In patients with mild renal impairment (creatinine clearance 51-80 mL/min) no adjustment in starting dose is recommended.
* In phase I studies, those with any abnormal renal function, since toxicity will likely be affected by the presence of any significant renal dysfunction.
* Cockcroft and Gault Equation:
* (140 - age \[yrs\]) (body wt \[kg\])
* Creatinine clearance for males = --------------
* (72) (serum creatinine \[mg/dL\])
* Creatinine clearance for females = 0.85 x male value

Primary outcomes:
measure: Feasibility & Efficacy of Chemo-radiation While Targeting Treatment, Based on: Original Tumor Characteristics; to be Followed by [Need for] Conventional Post-operative Chemotherapy
timeFrame: 12/2014 (up to 12 years)
Secondary outcomes:
measure: To Assess the Pathological Response Rate and Compare it to That Achieved in Our Previous Phase I-II Trials of Concurrent Chemo-radiation.
timeFrame: 12/2014 (up to 12 years)
measure: To Store Core Biopsies of the Original Tumor Before and After Treatment (From the Surgical Specimen) for Future Molecular Biology Studies in LABC.
timeFrame: 12/2014 (up to 12 years)
measure: To Acquire Descriptive Information on Patient Adherence to Therapy and on Quality of Life During Treatment.
timeFrame: 12/2014 (up to 12 years)
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Medical College of Cornell University
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Silvia C Formenti, M.D.
role: PRINCIPAL_INVESTIGATOR
References: